COMPARATIVE EFFICACY OF ORAL BISPHOSPHONATES IN POSTMENOPAUSAL OSTEOPOROSIS(according to the results of the VIBE retrospective study)
- Authors: Zotkin E1, Zubkova I1, Zotkin E2, Zubkova I2
-
Affiliations:
- Saint Petersburg Medical Academy of Postgraduate Education
- Issue: Vol 20, No 3 (2009)
- Pages: 57-60
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115355
- ID: 115355
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
The VIBE retrospective observational cohort study demonstrated that that risks for extravertebral and femoral neck fractures tended to reduce in patients given oral bisphosphonates for a year. This study confirmed that ibandronate was as effective as other bisphosphonates, such as alendronate and residronate. The risk of vertebral fractures turned out to be much less in compliant patients who received ibandronate in a dose of 150 mg once monthly than those who took other bisphosphonates weekly
Keywords
About the authors
E Zotkin
Email: ezotkin@mail.ru
I Zubkova
E Zotkin
Saint Petersburg Medical Academy of Postgraduate Education; Saint Petersburg Medical Academy of Postgraduate Education
I Zubkova
Saint Petersburg Medical Academy of Postgraduate EducationSaint Petersburg Medical Academy of Postgraduate Education
References
- Cadarette S., Katz J., Brookhart M. etal. Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture //Ann. Inter. Med. - 2008; 148:637-646.
- Cranney A., Wells G., Adachi R. Non-vertebral fracture reduction with high-versus low-dose ibandronate: meta-analysis of individual patient data // Ann. Rheum. Dis.-2007; 66 (2): 681.
- Eisman J., Garcia-Hernandes P., Ortiz-Luna G. et al. Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis; 2 years results from DIVA (abstract P316SA) // Osteoporosis Int. - 2006; 17:212.
- Harris S., Blumentals W., Miller P. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies // Current Medical Res. Opinion. -2008; 24:237-245.
- Harris S., Blumentals W., Poston S. et al. Fracture Risk with Once-Monthly Oral Ibandronate Compared with Weekly Bisphosphonates: Primary and Sensitivity Analyses from the evaluation of IBandronate Efficacy (VIBE) Database Fracture Study // ASBMR 30th Annual Meeting (September 12-16, 2008). - Poster#408.
- Reginster J., Adami S., Lacatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study//Ann. Rheum. Dis. -2006; 65:654-661.
- Reginster J., Neuprez A., Bruyere 0. Ibandronate in profile: drug characteristics and clinical efficacy // Expert Opin. Drug Metab. Toxicol. - 2008; 4:941-951.
- Silverman S., Warts N., Delmas P. et al. Effectiveness of bisphosphonates on nonvertevral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study // Osteoporosis Int. - 2007; 18:25-34.
Supplementary files
